PharmaPoint: Psoriasis – India Drug Forecast and Market Analysis to 2022

London (PRWEB) September 16, 2013

PharmaPoint: Psoriasis - India Drug Forecast and Market Analysis to 2022

Summary

GlobalData has released its new Country report, PharmaPoint: Psoriasis - India Drug Forecast and Market Analysis to 2022. There are no long-term effective therapies for Psoriasis (PsO), so this remains at the top of the list for unmet needs. While physicians agree that biologics are relatively safe and effective, these therapies are still lacking because of their immunosuppressant nature and lack of understanding as to their exact mechanism of action.

GlobalData is following during this forecast will likely not launch in India. However, the domestic company, Biocon, has developed and gained approval for the biologic Alzumab. In January 2013, this CD6 suppressant gained Indian drug approva, but will not launch until late Q3/early Q4, according to Biocon. Since Alzumab is an IV formulation, we expect it to be priced similarly to Remicade. This therapy will provide PsO patients a suitable option for symptom relief. Therefore, its uptake will provide additional revenue to the Indian PsO market.

Scope

Reasons to buy

1 Table of Contents 1 Table of Contents 4 1.1 List of Tables 7 1.2 List of Figures 8 2 Introduction 9 2.1 Catalyst 9 2.2 Related Reports 10 3 Disease Overview 12 3.1 Etiology and Pathophysiology 12 3.1.1 Etiology 12 3.1.2 Pathophysiology 14 3.2 Symptoms 17 4 Disease Management 18 4.1 Treatment Overview 19 4.2 India 24 4.2.1 Diagnosis 24 4.2.2 Clinical Practice 24 5 Competitive Assessment 26 5.1 Overview 26 5.2 Strategic Competitor Assessment 27 5.3 Product Profiles Major Brands 28 5.3.1 Taclonex (calcipotriene hydrate and betamethasone dipropionate) 28 5.3.2 Methotrexate Sodium (numerous generic names) 32 5.3.3 Minor Therapeutic Drug Classes Used in Psoriasis 36 5.3.4 Non-Pharmacological Therapy 37 6 Opportunity and Unmet Need 39 6.1 Overview 39 6.2 Unmet Needs 40 6.2.1 Improved Drug Safety and Efficacy Profiles 40 6.2.2 Biomarkers for Predicting Remission 41 6.2.3 More Cost-Effective Therapies Through Oral Formulation and Biosimilars 41 6.2.4 Education and Treatment of Psychological Factors Accompanying Psoriasis 42 6.2.5 An Effective Biologic/Systemic Topical Therapy 42 6.2.6 More Effective Treatment for Mild Psoriasis, Specifically UV Therapies 43 6.2.7 Physician Education About the Different Types of Psoriasis, not Just Plaque Psoriasis 43 6.3 Opportunities 44 6.4 Unmet Needs Gap Analysis 44 6.4.1 Predictive Tools for Diagnosis and Treatment 45 6.4.2 Target Specificity 45 6.4.3 Topical Biologic/Systemic Therapeutic Options 46 6.4.4 Helping Patients with Psychological Issues Associated with Psoriasis 46 7 Pipeline Assessment 47 7.1 Overview 47 7.2 Promising Drugs in Clinical Development 48 7.2.1 Alzumab (itolizumab) 50 7.2.2 Phase II Pipeline Products 55 7.2.3 Phase I Pipeline Products 57 7.2.4 Biosimilars Pipeline Products 58 8 Market Outlook 61 8.1 India 61 8.1.1 Forecast 61 8.1.2 Key Events 64 8.1.3 Drivers and Barriers 64 9 Appendix 67 9.1 Bibliography 67 9.2 Abbreviations 74 9.3 Methodology 78 9.4 Forecasting Methodology 78 9.4.1 Diagnosed Psoriasis Patients 78 9.4.2 Percent Drug-Treated Patients 79 9.4.3 Drugs Included in Each Therapeutic Class 79 9.4.4 General Pricing Assumptions 80 9.4.5 Individual Drug Assumptions 81 9.4.6 Generic Erosion 82 9.4.7 Pricing of Pipeline agents 82 9.5 Physicians and Specialists Included in this Study 83 9.6 Primary Research Prescriber Survey 84 9.7 About the Authors 85 9.7.1 Analysts 85 9.7.2 Global Head of Healthcare 86 9.8 About GlobalData 87 9.9 Disclaimer 87

1.1 List of Tables

Table 1: Immune Cells Involved in Lesions 14 Table 2: Symptoms of Psoriasis 17 Table 3: Minimal Investigative Measures Required Before Prescribing Biologics for Psoriasis 21 Table 4: Treatment Guidelines for Psoriasis 22 Table 5: Top Three Biologics Prescribed for Moderate to Severe Psoriasis by Market, 2012 23 Table 6: Leading Treatments for Psoriasis, 2013 27 Table 7: Product Profile Taclonex 29 Table 8: Taclonex SWOT Analysis, 2013 31 Table 9: Product Profile Methotrexate 33 Table 10: Methotrexate SWOT Analysis, 2013 35 Table 11: Summary of Minor Therapeutic Drug Classes for Psoriasis, 2013 36 Table 12: Overall Unmet Needs in Psoriasis Current Level of Attainment 40 Table 13: Clinical Unmet Needs in Psoriasis Gap Analysis, 2013 45 Table 14: Psoriasis Phase Pipeline, 2013 48 Table 15: Comparison of Therapeutic Classes in Development for Psoriasis, 2013 49 Table 16: Product Profile Alzumab 51 Table 17: Alzumab SWOT Analysis, 2013 53 Table 18: Global Sales Forecasts ($) for Alzumab, 20122022 54 Table 19: Phase II Psoriasis Pipeline, 2013 55 Table 20: Phase I Psoriasis Pipeline, 2013 57 Table 21: Biosimilars Pipeline, 2013 60 Table 22: Sales Forecasts ($) for Psoriasis in India, 20122022 62 Table 23: Key Events Impacting Sales for Psoriasis in India 20122022 64 Table 24: Psoriasis Market in India Drivers and Barriers, 20122022 64 Table 25: Physicians Surveyed, By Country 84

See more here:
PharmaPoint: Psoriasis - India Drug Forecast and Market Analysis to 2022